MX2015006852A - Ensayos para detectar autoanticuerpos neutralizantes para terapia biologica. - Google Patents

Ensayos para detectar autoanticuerpos neutralizantes para terapia biologica.

Info

Publication number
MX2015006852A
MX2015006852A MX2015006852A MX2015006852A MX2015006852A MX 2015006852 A MX2015006852 A MX 2015006852A MX 2015006852 A MX2015006852 A MX 2015006852A MX 2015006852 A MX2015006852 A MX 2015006852A MX 2015006852 A MX2015006852 A MX 2015006852A
Authority
MX
Mexico
Prior art keywords
neutralizing
therapy
present
biologic
assays
Prior art date
Application number
MX2015006852A
Other languages
English (en)
Spanish (es)
Inventor
Sharat Singh
Scott Hauenstein
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/802,117 external-priority patent/US20130266963A1/en
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2015006852A publication Critical patent/MX2015006852A/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/525Tumor necrosis factor [TNF]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2015006852A 2012-11-30 2013-11-27 Ensayos para detectar autoanticuerpos neutralizantes para terapia biologica. MX2015006852A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261732251P 2012-11-30 2012-11-30
US13/802,117 US20130266963A1 (en) 2011-07-06 2013-03-13 Assay for detecting neutralizing autoantibodies to biologic therapy
PCT/IB2013/060458 WO2014083520A2 (en) 2012-11-30 2013-11-27 Assays for detecting neutralizing autoantibodies to biologic therapy

Publications (1)

Publication Number Publication Date
MX2015006852A true MX2015006852A (es) 2015-09-16

Family

ID=50828561

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006852A MX2015006852A (es) 2012-11-30 2013-11-27 Ensayos para detectar autoanticuerpos neutralizantes para terapia biologica.

Country Status (13)

Country Link
EP (1) EP2926136A2 (enExample)
JP (1) JP2016502091A (enExample)
KR (1) KR20150088890A (enExample)
CN (1) CN105074461A (enExample)
AU (1) AU2013350817A1 (enExample)
BR (1) BR112015012482A2 (enExample)
CA (1) CA2892766A1 (enExample)
HK (1) HK1215969A1 (enExample)
IL (1) IL238995A0 (enExample)
MX (1) MX2015006852A (enExample)
RU (1) RU2015125739A (enExample)
SG (2) SG11201504097PA (enExample)
WO (1) WO2014083520A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010315547C1 (en) 2009-10-26 2015-06-04 Société des Produits Nestlé S.A. Assays for the detection of anti-TNF drugs and autoantibodies
AU2011317149B2 (en) 2010-10-18 2015-05-07 Société des Produits Nestlé S.A. Methods for determining anti-drug antibody isotypes
RU2013158256A (ru) 2011-07-06 2015-07-10 Нестек С.А. АНАЛИЗЫ ДЛЯ ОБНАРУЖЕНИЯ НЕЙТРАЛИЗУЮЩИХ АУТОАНТИТЕЛ ДЛЯ БИОЛОГИЧЕСКОЙ ТЕРАПИИ TNFα
ES2735085T3 (es) 2014-12-05 2019-12-16 Nestle Sa Ensayos de cambio de movilidad homogéneos indirectos para la detección de agentes biológicos en muestras de pacientes
US11085931B2 (en) 2015-01-09 2021-08-10 W. Health L.P. Universal assay for determining the quantity of TNFα inhibitory drugs and their corresponding anti-drug-antibodies
EP3482199A1 (en) * 2016-07-08 2019-05-15 Atonomics A/S A universal assay for determining the quantity of therapeutic monoclonal antibodies and their corresponding anti-drug-antibodies in samples
AU2018241286B2 (en) 2017-03-31 2025-03-13 Ablynx N.V. Improved immunogenicity assays
JP7570421B2 (ja) * 2020-01-02 2024-10-21 エフ. ホフマン-ラ ロシュ アーゲー Ada応答特定アッセイ
CN111024958B (zh) * 2020-03-11 2020-06-23 同昕生物技术(北京)有限公司 用于检测单抗药物和抗单抗药物抗体的试剂及其应用
CN112730846B (zh) * 2020-12-18 2023-12-15 安渡生物医药(杭州)有限公司 一种用于小鼠血样检测免疫复合物的方法
CN114047343B (zh) * 2022-01-13 2022-05-31 美迪西普亚医药科技(上海)有限公司 双耐受型抗IgE单抗药物的免疫原性分析试剂盒及其使用方法和应用
CN117871856A (zh) * 2023-12-15 2024-04-12 首都医科大学附属北京地坛医院 可溶性因子在无症状神经梅毒检测中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010315547C1 (en) * 2009-10-26 2015-06-04 Société des Produits Nestlé S.A. Assays for the detection of anti-TNF drugs and autoantibodies
CN102884433A (zh) * 2010-04-29 2013-01-16 塞拉蒂亚戈公司 用于检测抗体的方法
AU2011317149B2 (en) * 2010-10-18 2015-05-07 Société des Produits Nestlé S.A. Methods for determining anti-drug antibody isotypes
ES2530175T3 (es) * 2011-02-17 2015-02-26 Nestec S.A. Ensayos para la detección de autoanticuerpos contra fármacos anti-TNF
RU2013158256A (ru) * 2011-07-06 2015-07-10 Нестек С.А. АНАЛИЗЫ ДЛЯ ОБНАРУЖЕНИЯ НЕЙТРАЛИЗУЮЩИХ АУТОАНТИТЕЛ ДЛЯ БИОЛОГИЧЕСКОЙ ТЕРАПИИ TNFα

Also Published As

Publication number Publication date
WO2014083520A3 (en) 2014-07-31
RU2015125739A (ru) 2017-01-13
JP2016502091A (ja) 2016-01-21
IL238995A0 (en) 2015-07-30
WO2014083520A2 (en) 2014-06-05
BR112015012482A2 (pt) 2017-07-11
CN105074461A (zh) 2015-11-18
KR20150088890A (ko) 2015-08-03
SG11201504097PA (en) 2015-06-29
AU2013350817A1 (en) 2015-06-11
SG10201703210XA (en) 2017-06-29
CA2892766A1 (en) 2014-06-05
EP2926136A2 (en) 2015-10-07
HK1215969A1 (zh) 2016-09-30

Similar Documents

Publication Publication Date Title
MX2015006852A (es) Ensayos para detectar autoanticuerpos neutralizantes para terapia biologica.
MX343324B (es) Ensayos para detectar auto anticuerpos neutralizadores de la terapia biologica con tnf alpha.
MX343327B (es) Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa.
MX390772B (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
BR112014031365A2 (pt) métodos de detectar doenças ou condições
BRPI1007321A2 (pt) métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo.
MX349561B (es) Método para detectar nucleosomas que contienen variantes de histonas.
MX343328B (es) Analisis para la deteccion de farmacos anti-tnf y anticuerpos.
BR112016004305A2 (pt) métodos diagnósticos e composições para tratamento de glioblastoma
WO2014153099A3 (en) Method for using exhaled breath to determine the presence of drug
BR112013006683A2 (pt) diagnóstico de câncer de mama
NZ609493A (en) Diagnosis and treatments relating to th2 inhibition
BR112015011359A2 (pt) método para indicar uma presença ou não presença de câncer de próstata agressivo
EP2569635A4 (en) METHOD FOR DIAGNOSIS AND / OR TREATMENT OF ENZEPHALITIS OR EPILEPSY
WO2011146945A3 (en) Alk and ros kinase in cancer
HK1213892A1 (zh) Tec家族激酶抑制剂疗法的伴随诊断
SG10201806729VA (en) Novel assay to detect human periostin
BR112015013771A2 (pt) biomarcador preditivo de resposta ao tratamento de ativador do receptor alfa 7 nicotínico de acetilcolina
BR112013013457A2 (pt) métodos para identificar um paciente ou sujeito, para prever a sensibilidade de um sujeito, para identificar sujeitos que têm doença de parkinson e para determinar a resposta do sujeito à terapia e ensaio para seleção de compostos e composições
EP4591867A3 (en) Methods for detecting bordetella
WO2011085057A3 (en) Methods for detecting insulin autoantibody
MX2014011045A (es) Metodo para seleccionar o identificar un sujeto para la terapia antagonista vib.
MX2015015023A (es) Metodo para la determinacion de cobre libre.
IN2015MN00140A (enExample)
MX2021009281A (es) Metodos de deteccion de legionella.